Cover image for Vol. 13 Issue 4

Editorial Board Chairs: Karl-Heinz Altmann, Antonello Mai, Rainer Metternich. Editor: David Peralta

Impact Factor: 3.225

ISI Journal Citation Reports © Ranking: 2016: 17/60 (Chemistry Medicinal); 73/257 (Pharmacology & Pharmacy)

Online ISSN: 1860-7187

Associated Title(s): Angewandte Chemie International Edition, Chemistry - A European Journal, Chemistry – An Asian Journal, ChemBioChem, Medicinal Research Reviews, Molecular Informatics

November 04, 2009

Steven Ley Awarded the 2009 Heinrich Wieland Prize

Steven Ley Awarded the 2009 Heinrich Wieland PrizeThis year's Heinrich Wieland Prize went to Professor Steven V. Ley of Cambridge University (UK) in recognition of his outstanding contributions to the fields of organic synthesis, natural product characterization, and structural analysis. Professor Ley was awarded the prize, which comes with an endowment of 50,000 euros, on October 29 at the Ludwig Maximilian University in Munich. The Heinrich Wieland Prize has been awarded annually since 1964 for recognizing innovative excellence in chemistry, biochemistry, and physiology.

Professor Ley has carried out the total synthesis of more than 120 compounds, most of which have important biological activity. His research group recently reported the total synthesis of the antifungal marine natural products, bengazoles A and B. Along with his work in the total synthesis of natural products, Professor Ley has played a leading role in the development of green chemistry, automated synthesis, and techniques for the production of pharmaceutical leads, much of which have already found application in industrial settings.

ChemMedChem is proud to have Professor Ley as a member of its International Advisory Board, and he has made numerous valuable contributions to the journal's success. Last year Professor Ley and colleagues reported their work on spiroketals and bicyclic acetals as potential chemotherapeutic agents for B-cell chronic lymphocytic leukemia in Volume 3 (pp. 1922–1935). The Essay by Ley et al. in Volume 2 (pp. 768–788), "Pharmaceutical Strategy and Innovation: An Academics Perspective", is an engaging and informative read that covers the current challenges faced by the pharmaceutical industry in balancing the demands of development timeframes, investor returns, and scientific innovation.

Your Comment...

[Browse more news]